LumiraDx ships COVID, flu tests to Europe, ups revenues

By LabPulse.com staff writers

January 12, 2022 -- LumiraDx has started shipping its point-of-care COVID-19 and flu A/B microfluidic antigen tests to Europe. The new products are expected to boost the company's revenues for the last quarter of 2021.

The company's revenues for the fourth quarter of 2021 are expected to be $119 million, in comparison to revenues of $101 million during that same period of 2020, according to preliminary results. These tests are expected to account for about $77 million of revenue in the fourth quarter of 2021, which has been driven by higher testing rates associated with the omicron variant of SARS-CoV-2.

For 2021, the company anticipates full-year 2021 revenues of $422 million compared to revenues of $139 million the year before.

The company began shipping the COVID-19 test to Europe after receiving a CE Mark for it in December. Currently, LumiraDx is awaiting emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the antigen test.

AACC to offer onsite COVID testing at annual meeting
The American Association for Clinical Chemistry (AACC) will offer free onsite COVID-19 testing at its annual meeting, which is being held September 26-30...
LumiraDx launches COVID surveillance test in U.S.
LumiraDx is launching a portable, rapid onsite COVID-19 surveillance test in the U.S., the company announced.

Copyright © 2022 LabPulse.com

Last Updated ls 1/12/2022 2:34:48 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current